CpG islands in MyD88 and ASC/PYCARD/TMS1 promoter regions are differentially methylated in head and neck squamous cell carcinoma and primary lung squamous cell carcinoma

Scientific paper - Original scientific paper

• Author: Maja Šutić
• Author: Jurica Baranašić
• Author: Lana Kovač Bilić
• Author: Mario Bilić
• Author: Antonija Jakovčević
• Author: Luka Brčić
• Author: Sven Seiwerth
• Author: Marko Jakopović
• Author: Miroslav Samaržija
• Author: Ulrich Zechner
• Author: Jelena Knežević
• Author's institution: University of Zagreb; School of Medicine; (Department of Internal Medicine)
• Author's institution: University of Zagreb; School of Medicine; (Department of Othorhinolaryngology and Head and Neck Surgery)
• Author's institution: University of Zagreb; School of Medicine; (Department of Pathology)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Internal Medicine
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Otorhinolaryngology
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Pathology

Abstract (english)

Background: Patients with head and neck squamous cell carcinoma (HNSCC) can develop lung squamous cell carcinoma (LuSCC), which could be the second primary tumor or HNSCC metastasis. Morphologically it is difficult to distinguish metastatic HNSCC from a second primary tumor which presents a significant diagnostic challenge. Differentiation of those two malignancies is important because the recommended treatments for metastatic HNSCC and primary LuSCC differ significantly. We investigated if the quantification of the promotor methylation status in HNSCC and LuSCC differs.
-----
Methods: Primary HNSCC (N = 36) and LuSCC (N = 17) were included in this study. Methylation status in the ASC/TMS1/PYCARD (apoptosis-associated speck-like protein containing a caspase recruitment domain; 8 CpG sites) and MyD88 (Myeloid differentiation primary response protein 88; 10 CpG sites) promoters was analyzed. Bisulfite converted DNA, isolated from tumor tissue was quantified using pyrosequencing. Results of pyrosequencing analysis were expressed as a percentage for each tested CpG site. Receiver-operating characteristic (ROC) curve analysis was used for the evaluation of the diagnostic properties of selected biomarkers.
-----
Results: CpG sites located in the promoters of ASC/TMS1/PYCARD_CpG8 (- 65 upstream) and MyD88_CpG4 (- 278 upstream) are significantly hypermethylated in the HNSCC when compared with LuSCC (p ≤ 0.0001). By performing ROC curve analysis we showed that corresponding areas under the curve (AUC) were 85-95%, indicating that selected CpG sites are useful for a distinction between primary LuSCC and primary HNSCC.
-----
Conclusions: Results of the present study indicate that there is a significant difference in the methylation status of tested genes between primary HNSCC and LuSCC. However, to prove this approach as a useful tool for distinguishing second primary LuSCC from HNSCC metastasis, it would be necessary to include a larger number of samples, and most importantly, metastatic samples.

• Keywords (english): CpG; Diagnostic biomarker; HNSCC; Lung; Methylation; Second primary tumor
• Language: english
• Publication type: Scientific paper - Original scientific paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Diagnostic Pathology
• Numbering: vol. 16, 17
• e-ISSN: 1746-1596
• DOI: https://doi.org/10.1186/s13000-021-01078-3
• URN:NBN: urn:nbn:hr:105:184328
• Publication: 2021-02-26
• Project: Number: IP-2016-06-1441; Title (croatian): Genetički i epigenetički biomarkeri urođene imunosti u KOPB-u i karcinomu pluća; Acronym: LungInflaCare; Leader: Jelena Knežević; Jurisdiction: Croatia; Funding stream: IP
• Document URL: https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-021-01078-3
• Type of resource: Text
• Access conditions: Open access
• Created on: 2021-06-25 09:36:45